Does CYP2C19 loss-of-function allele carrier status increase the risk of stroke and composite vascular events in patients with ischemic stroke or TIA treated with clopidogrel?
CYP2C19 loss-of-function allele carriers have reduced clopidogrel efficacy, leading to a higher risk of recurrent stroke and vascular events after an ischemic stroke or TIA.
Carriers of CYP2C19 loss-of-function alleles are at greater risk of stroke and composite vascular events than noncarriers among patients with ischemic stroke or TIA treated with clopidogrel.
Pan et al. (Thu,) studied this question.